Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

5/4/2010, Tuesday

FOR RELEASE 5/4/2010, Tuesday

Bausch + Lomb Introduces New Soothe® Xtra Hydration Dry Eye Therapy Lubricant Eye Drops

Unique, Dual-Action Therapy Moisturizes and Restores the Deficient Aqueous and Mucin Layers of the Tear Film

MADISON, N.J. – Bausch + Lomb today announced the U.S. launch of new Soothe® Xtra Hydration lubricant eye drops. Building on the success of the SootheXP  Xtra Protection formula, new Soothe Xtra Hydration provides a comprehensive over-the-counter portfolio for patients with dry eyes.

The Soothe portfolio is now aligned with the most recent international Dry Eye Workshop (DEWS) sponsored by the Tear Film & Ocular Surface Society. DEWS created a new definition of dry eye and helped develop two major classifications of dry eye – aqueous-deficient dry eye and evaporative dry eye.

New Soothe Xtra Hydration, for aqueous-deficient dry eye therapy, moisturizes and restores the deficient aqueous and mucin layers of the tear film to provide lasting hydration and comfort. It will be available at major retailers in May.

SootheXP  Xtra Protection, for evaporative dry eye therapy, re-establishes the lipid layer of the tear film to provide up to eight hours of relief. The product is widely available at major retailers.


About Bausch + Lomb
Bausch + Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch + Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at

®/™ denote trademarks of Bausch & Lomb Incorporated.


Number of views (1886)/Comments (0)